Acteryon is an innovative biotechnology company dedicated to the research and development of new technologies and products based on bacteriophages. Our business strategy is based on developing new therapeutics in early phases of R&D with a view to then enter into collaboration deals for pre-clinical and/or clinical development. All this is embedded in a seasoned team of professionals with extensive clinical development experience.
Our strategic goal is to become a global leader in novel natural product development, platform provision and manufacturing in the GMP standard for industrial and pharmaceutical application. We embrace a policy of open access and knowledge exchange. We mean to become an active member of the phage community and promote biotechnological discoveries and applications.
Research on bacteriophages goes back a century, however, the discovery and widespread application of antibiotics prevented its further development. The recent and alarming rise of antibiotic-resistant infections coupled with the inability of conventional therapy to deal with the situation has led to a renewed interest in phages.
In response to this and in anticipation of a growing demand for phage products and therapies, we are determined to establish a state-of-the art R&D and manufacturing facilities built to GMP and GLP guidelines in order to provide a platform for the further development of the re-emerging field of bacteriophages.
ACTERYON Sp. z o.o.
Al. Zwycięestwa 96/98